On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Takeda Snares US Approval for Orzeyful in Narcolepsy Type 1
August 7, 2026
-
REGULATORY Nakai Tapped as MHLW’s Top Pharmacy Officer; Ohara to Steer Drug Pricing Reform
August 7, 2026
-
REGULATORY Sarclisa SC, Joenja, Kineret, and 7 More Drugs Bound for NHI Listing
August 6, 2026
-
REGULATORY Chuikyo Clears NHI Listing for Oncolys’ Telomelysin
August 6, 2026
-
BUSINESS AstraZeneca Japan Chief Says MFN Response Requires Drug Pricing Reform
August 5, 2026
-
REGULATORY Outgoing MHLW Pharmacy Chief Eyes AI as Next Frontier for Drug Regulation
August 4, 2026
-
BUSINESS Lilly Blasts Mounjaro Price Cut, Warns over Japan Investment Appeal
August 4, 2026
-
COMMENTARY Signs of Shift in Japan’s Drug Policy, but Cost Pressures Persist
August 3, 2026
-
ORGANIZATION JPMA Chief Seeks Concrete Reforms to Reward Innovation after Honebuto
July 31, 2026
-
BUSINESS Astellas Expands AI Drug Discovery to TPDs, Engineered Proteins
July 30, 2026
-
BUSINESS Some Drug Plants Halt Operations after Kumamoto Temblor, Supplies Unaffected
July 30, 2026
-
BUSINESS Drug Makers, Wholesalers Rush to Gauge Kumamoto Quake Impact
July 29, 2026
-
ORGANIZATION Radiopharma Group Seeks Faster NHI Coverage for PET Imaging Agents
July 28, 2026
-
REGULATORY Japan Panel Green-Lights GSK’s Hep B Drug, Brinsupri, Hyrnuo
July 28, 2026
-
COMMENTARY Rare Cancer Case Raises New Questions about AAV Gene Therapy Safety
July 27, 2026
-
REGULATORY Japan Enacts Revised Immunization Act, Opens Way for RSV Antibodies under NIP
July 27, 2026
-
REGULATORY Japan to Clarify Non-Clinical Data Waivers for Repurposed Drugs, Ease Sakigake Rules
July 24, 2026
-
ORGANIZATION CES Waivers Could Slow Biosimilar Uptake without Better Communication: Industry
July 23, 2026
-
REGULATORY Japan Sees Limited Impact from Planned US Tariffs on Generics
July 23, 2026
-
REGULATORY Ishin Lawmaker Seeks Full Chuikyo Seat for Industry, but with Fiscal Responsibility
July 22, 2026
ページ
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Japan will trim the NHI price of Eli Lilly Japan’s Alzheimer’s treatment Kisunla (donanemab) by 3.93% under the cost-effectiveness assessment…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…